8 completed, 2 withdrawn. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 7, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow GSK598809: new trials by email Literature Review of GSK598809 trials Research Report on GSK598809
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention GSK598809, Placebo - Nicotine Dependence | Phase 2 | Completed | Massachusetts General Hospital | 84 | 2010-08-01 | 2017-02-23 |
| Effects of GSK598809 on Brain Activation in Abstinent Alcoholics GSK598809 - Substance Dependence, Alcohol Dependence | Phase 1 | Withdrawn | GlaxoSmithKline | 2009-05-01 | 2015-04-17 | |
| Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement GSK598809 Capsules, GSK598809 Placebo Capsules - Substance Dependence | Phase 1 | Completed | GlaxoSmithKline | 24 | 2008-12-18 | 2017-06-20 |
| Relapse Prevention Study in Newly Abstinent Smokers GSK598809, Nicotine Replacement Transdermal Patch, Placebo - Substance Dependence | Phase 2 | Withdrawn | GlaxoSmithKline | 2008-12-01 | 2016-02-15 | |
| EtOH Interaction Study GSK598809, Ethanol - Substance Dependence | Phase 1 | Completed | GlaxoSmithKline | 20 | 2008-09-29 | 2017-07-18 |
| A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers GSK598809, Placebo - Substance Dependence | Phase 1 | Completed | GlaxoSmithKline | 18 | 2008-06-09 | 2017-08-03 |
| A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward GSK598809 - Substance Dependence | Phase 1 | Completed | GlaxoSmithKline | 29 | 2008-02-25 | 2017-07-21 |
| Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males. GSK598809, using [11C]-(+)-PHNO - Healthy Subjects | Phase 1 | Completed | GlaxoSmithKline | 25 | 2007-04-01 | 2010-10-28 |
| A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809 GSK598809, Placebo - Substance Dependence | Phase 1 | Completed | GlaxoSmithKline | 12 | 2007-03-20 | 2017-08-07 |
| Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809 GSK598809, Placebo, Caffeine - Substance Dependence | Phase 1 | Completed | GlaxoSmithKline | 104 | 2007-03-01 | 2017-07-31 |
Substance-Related Disorders (8) · Alcoholism (2) · Smoking (2) · Tobacco Use Disorder (2) · Behavior (1) · Food Addiction (1) · Obesity (1) · Overweight (1) · Smoking Cessation (1)
GlaxoSmithKline (9) · Massachusetts General Hospital (1)
United States (3) · Germany (2) · United Kingdom (2) · Canada (1) · Netherlands (1)
Eden Evins, MD, MPH (1) · Maurizio Fava, MD (1)
U01DA019378 (1)